Synthesis of linear, β-cyclodextrin-based polymers and their camptothecin conjugates

被引:180
作者
Cheng, JJ
Khin, KT
Jensen, GS
Liu, AJ
Davis, ME [1 ]
机构
[1] CALTECH, Div Chem Engn, Pasadena, CA 91125 USA
[2] Insert Therapeut Inc, Pasadena, CA 91107 USA
关键词
D O I
10.1021/bc0340924
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
6(A),6(D) -Bis-(2-amino-2-carboxylethylthio)-6(A) 6(D)-dideoxy-beta-cyclodextrin 1, a diamino acid derivative of beta-cyclodextrin, is synthesized and condensed with difunctionalized PEG comonomers to give linear, high molecular weight (M-w over 50 kDa) beta-cyclodextrin-based polymers (2-4) with pendant functionality (carboxylate). 2-4 are all highly soluble in aqueous solutions (over 200 mg/mL). 20-O-trifluoroglycinylcamptothecin, 5a, and 20-O-trifluoroglycinylglycinylglycinylcamptothecin, 5b, are synthesized and conjugated to 2 to give polymer- camptothecin (CPT) prodrugs. The solubility of CPT is increased by more than three orders of magnitude when it is conjugated to 2. The rates of CPT release from the conjugates HGGG6 (high molecular weight polymer (M-w 97 kDa), glyglygly linker and 6 wt % CPT loading) and HG6 (high MW polymer (M-w 97 kDa), gly linker and 6 wt % CPT loading) in either mouse or human plasma are dramatically accelerated over the rates of pure hydrolysis at pH = 7.4, indicating the presence of enzymatic cleavage as a rate-determining step at this pH in the release of the CPT. The pH of aqueous solution has a large effect on hydrolysis rate of CPT from HGGG6 and HG6; the lower the pH, the slower the rate in the range at 4.1 less than or equal to pH less than or equal to 13.1. The IC50's of polymer 2e, CPT, and the CPT conjugates HG6 and HGGG6 are found to be cell-line dependent with LS174T, HT29, A2780, and PC3 cells using in vitro MTT assays. The parent polymer 2e has very low toxicity to all cultured cells tested.
引用
收藏
页码:1007 / 1017
页数:11
相关论文
共 34 条
[1]   Synthesis and in vivo antitumor activity of poly(L-glutamic acid) conjugates of 20(S)-camptothecin [J].
Bhatt, RL ;
de Vries, P ;
Tulinsky, J ;
Bellamy, G ;
Baker, B ;
Singer, JW ;
Klein, P .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (01) :190-193
[2]   Polymer-bound camptothecin: initial biodistribution and antitumour activity studies [J].
Caiolfa, VR ;
Zamai, M ;
Fiorino, A ;
Frigerio, E ;
Pellizzoni, C ;
d'Argy, R ;
Ghiglieri, A ;
Castelli, MG ;
Farao, M ;
Pesenti, E ;
Gigli, M ;
Angelucci, F ;
Suarato, A .
JOURNAL OF CONTROLLED RELEASE, 2000, 65 (1-2) :105-119
[3]  
CHENG J, UNPUB CANC RES
[4]  
Conover CD, 1999, ANTI-CANCER DRUG DES, V14, P499
[5]  
DUNCAN R, 1984, ADV POLYM SCI, V57, P51
[6]  
Duncan R, 1996, STP PHARMA SCI, V6, P237
[7]   The dawning era of polymer therapeutics [J].
Duncan, R .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (05) :347-360
[8]   Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic [J].
Duncan, R ;
Gac-Breton, S ;
Keane, R ;
Musila, R ;
Sat, YN ;
Satchi, R ;
Searle, F .
JOURNAL OF CONTROLLED RELEASE, 2001, 74 (1-3) :135-146
[9]   CYCLODEXTRIN POLYMERS IN THE PHARMACEUTICAL-INDUSTRY [J].
FENYVESI, E .
JOURNAL OF INCLUSION PHENOMENA, 1988, 6 (05) :537-545
[10]   New class of polymers for the delivery of macromolecular therapeutics [J].
Gonzalez, H ;
Hwang, SJ ;
Davis, ME .
BIOCONJUGATE CHEMISTRY, 1999, 10 (06) :1068-1074